Biotechnology company Genentech is licensing a process from a start-up enterprise that discovers small molecule drugs from naturally occurring microbes found in soil. . . . → Read More: Genentech Gains Microbe Drug Discovery Tech in $1B Deal
|
|||||
|
|
 Comments are closed  Intellectual property  biomedical, biotechnology, chemistry, entrepreneurs, equity, genomics, investment, licensing, life sciences, pharmaceuticals, physical sciences, university, venture capital 
More people now use crowdfunding campaigns to raise money to cover families’ medical costs, but the technique is also used to support treatments from stem cell clinics that exaggerate their outcomes and minimize their risks. . . . → Read More: Crowdfunding Found Supporting Dubious Stem Cell Clinics Comments are closed Regulations biomedical, Canada, crowdfunding, health care, pharmaceuticals, stem cells 
An enterprise developing a synthetic antibody to treat breast cancer, spun-off from a University at Buffalo research lab, is taking part in a federal program to advance the treatments to clinical trials. . . . → Read More: Univ. Spinoff Qualifies for NIH Clinical Program Comments are closed New products biomedical, biotechnology, cancer, clinical trials, entrepreneurs, licensing, life sciences, NIH, pharmaceuticals, university 
A university lab is teaming up with a local biotechnology company to develop realistic models of tumors from individual cancer patients, enabling more personalized treatment options. . . . → Read More: 3-D Models Devised to Simulate Patients’ Tumors Comments are closed Joint ventures/collaborations, New products biomedical, biotechnology, cancer, engineering, licensing, life sciences, medical device, pharmaceuticals, physical sciences, university 
An award from the Bill and Melinda Gates Foundation is supporting research by a digital drug discovery company and university lab into use of artificial intelligence to find new drugs for treating malaria. . . . → Read More: Gates Grant Funds A.I. for Malaria Drug Discovery Comments are closed Finance, Joint ventures/collaborations biomedical, engineering, genomics, grant, life sciences, mathematics, pharmaceuticals, physical sciences, university 
A clinical trial is recruiting participants to test a vaccine to protect against a variety of influenza strains, instead of today’s vaccines designed to prevent infections from specific strains expected in a given year. . . . → Read More: Trial Underway Testing Universal Flu Vaccine Comments are closed New products, Regulations biomedical, biotechnology, clinical trials, health care, Israel, life sciences, NIH, pharmaceuticals, university 
A start-up enterprise is discovering therapies to address a variety of disorders that result from faulty cell degradation processes known as autophagy, which when functioning normally contribute to cell health. . . . → Read More: New Cell Therapy Company Raises $58.5M in Early Funds Comments are closed Finance biomedical, biotechnology, entrepreneurs, equity, investment, life sciences, pharmaceuticals, university, venture capital 
A bioengineering center at Harvard University and a biotechnology company are creating a process for genetically editing human cell lines to produce virus-resistant synthetic proteins for research and therapies. . . . → Read More: Cellectis, Wyss Inst. Partner on Recoding Human Genome Comments are closed Joint ventures/collaborations biomedical, biotechnology, engineering, genomics, life sciences, pharmaceuticals, university 
A vaccine to protect against peanut allergies, given as a nanoscale droplets suspended in a nasal spray, is shown to prevent allergic reactions in tests with lab mice sensitized to peanuts. . . . → Read More: Nasal Spray Vaccine Shown to Control Peanut Allergies Comments are closed New products biomedical, engineering, entrepreneurs, life sciences, nanotechnology, patent, pharmaceuticals, university A biotechnology enterprise developing gene therapies for rare inherited diseases and neurological disorders is being acquired by pharmaceutical company Novartis AG for $8.7 billion. . . . → Read More: Gene Therapy Biotech Acquired in $8.7 Billion Deal Comments are closed Finance biomedical, biotechnology, clinical trials, equity, Europe, FDA, genomics, investment, life sciences, merger, pharmaceuticals |
One Blood Test Fits All Diseases A Thinking Person’s Artificial Intelligence Do You Want Your Bacon CRISPR? Health Care, Precisely One Person at a Time Let Guinea Pigs be Guinea Pigs Look Out Pharma. The Tech Industry is After You |
|||
|
Copyright © 2018 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
